2393P Prospective monitoring of prostate specific membrane antigen (PSMA) in biochemically recurrent prostate cancer (BCR): Preliminary data from 1 Year follow-up
Ravi A. Madan(National Cancer Institute), Peter Choyke(National Institutes of Health), Esther Mena Gonzalez(National Cancer Institute), Melissa L. Abel(National Institutes of Health), Martin Häusler(RWTH Aachen University), Edwin M. Posadas(Cedars-Sinai Medical Center), Jeanny B. Aragon‐Ching(Inova Fairfax Hospital), Amy Hankin(National Institutes of Health), Geoffrey T. Chestnut(Walter Reed National Military Medical Center), Marijo Bilušić(National Institutes of Health), Catherine H. Marshall(Mayo Clinic Hospital), Fatima Karzai(National Institutes of Health), N. Williams(National Cancer Institute), Allison Betof Warner(Memorial Sloan Kettering Cancer Center), Liza Lindenberg(National Cancer Institute), Russell K. Pachynski, Helen Moon(National Cancer Institute), William D. Figg(National Institutes of Health), Deborah Jolissaint(Walter Reed National Military Medical Center), Laureen Sena
Cited by 0
Related Papers
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
American Cancer Society prostate cancer survivorship care guidelines
|CA A Cancer Journal for Clinicians|2014|402
Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations
|JNCI Journal of the National Cancer Institute|2006|345